MHRA схвалила безін’єкційний препарат для невідкладної терапії алергічних реакцій

Investment of 350 million EUR in state-of-the-art research infrastructure is Boehringer Ingelheim’s largest single investment in Germany to date Boehringer Ingelheim strengthens innovation power and development of biopharmaceuticals, which account…

"Biopharma Plasma" LLC had a meeting with representatives of "Sperko Ukraine" and "Farmlyga" companies. During the conversation, the companies raised the issue of collaboration. The negotiation process led to agreements…